PMC:7386875 / 55644-57480 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T521","span":{"begin":385,"end":402},"obj":"Body_part"},{"id":"T522","span":{"begin":397,"end":402},"obj":"Body_part"},{"id":"T523","span":{"begin":521,"end":532},"obj":"Body_part"},{"id":"T524","span":{"begin":534,"end":543},"obj":"Body_part"},{"id":"T525","span":{"begin":599,"end":607},"obj":"Body_part"},{"id":"T526","span":{"begin":1370,"end":1374},"obj":"Body_part"}],"attributes":[{"id":"A521","pred":"fma_id","subj":"T521","obj":"http://purl.org/sig/ont/fma/fma66772"},{"id":"A522","pred":"fma_id","subj":"T522","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A523","pred":"fma_id","subj":"T523","obj":"http://purl.org/sig/ont/fma/fma63916"},{"id":"A524","pred":"fma_id","subj":"T524","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A525","pred":"fma_id","subj":"T525","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A526","pred":"fma_id","subj":"T526","obj":"http://purl.org/sig/ont/fma/fma24728"}],"text":"The emergence of the SARS-CoV-2 virus and the ensuing global pandemic has presented unprecedented healthcare and economic challenges. A key clinical feature of severe COVID-19 seems to be a highly prothrombotic state, which is linked to excess rates of arterial, venous and microvascular thrombosis, and adverse clinical outcomes. Emerging evidence suggests that SARS-CoV-2 can infect endothelial cells with the associated immune response and ensuing activation of inflammatory pathways resulting in dysregulation of the endothelium, leukocyte activation, NET generation, complement deposition, and platelet consumption. These pathways can conspire to unleash a prothrombotic state (immunothrombosis), which may result in significant thrombotic complications. Accordingly, there remains much interest, and an urgent clinical need, to precisely delineate the mechanisms by which SARS-CoV-2 infection causes thrombotic complications in the hope that new insights into this process will yield novel therapeutic approaches. This is especially pressing in the absence of an effective therapy or vaccine for SARS-CoV-2. Thus, in the context of COVID-19 the intersection of innate and adaptive immunity, inflammation, and thrombosis has been thrust into the global spotlight, and the challenge is now to urgently find therapeutic concepts to disrupt this unholy trinity in the face of a global pandemic. The growing awareness and understanding of thrombotic complications in patients with SARS-CoV-2 infection will contribute to a more rigorous diagnostic approach resulting in the earlier detection of thrombotic events. Importantly, the shift towards the early institution of antithrombotic therapy for the prevention and treatment of COVID-19-associated thrombosis will hopefully translate into improved outcomes for patients with COVID-19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T69","span":{"begin":521,"end":532},"obj":"Body_part"},{"id":"T70","span":{"begin":1370,"end":1374},"obj":"Body_part"}],"attributes":[{"id":"A69","pred":"uberon_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/UBERON_0001986"},{"id":"A70","pred":"uberon_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"}],"text":"The emergence of the SARS-CoV-2 virus and the ensuing global pandemic has presented unprecedented healthcare and economic challenges. A key clinical feature of severe COVID-19 seems to be a highly prothrombotic state, which is linked to excess rates of arterial, venous and microvascular thrombosis, and adverse clinical outcomes. Emerging evidence suggests that SARS-CoV-2 can infect endothelial cells with the associated immune response and ensuing activation of inflammatory pathways resulting in dysregulation of the endothelium, leukocyte activation, NET generation, complement deposition, and platelet consumption. These pathways can conspire to unleash a prothrombotic state (immunothrombosis), which may result in significant thrombotic complications. Accordingly, there remains much interest, and an urgent clinical need, to precisely delineate the mechanisms by which SARS-CoV-2 infection causes thrombotic complications in the hope that new insights into this process will yield novel therapeutic approaches. This is especially pressing in the absence of an effective therapy or vaccine for SARS-CoV-2. Thus, in the context of COVID-19 the intersection of innate and adaptive immunity, inflammation, and thrombosis has been thrust into the global spotlight, and the challenge is now to urgently find therapeutic concepts to disrupt this unholy trinity in the face of a global pandemic. The growing awareness and understanding of thrombotic complications in patients with SARS-CoV-2 infection will contribute to a more rigorous diagnostic approach resulting in the earlier detection of thrombotic events. Importantly, the shift towards the early institution of antithrombotic therapy for the prevention and treatment of COVID-19-associated thrombosis will hopefully translate into improved outcomes for patients with COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T406","span":{"begin":21,"end":29},"obj":"Disease"},{"id":"T407","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"T408","span":{"begin":288,"end":298},"obj":"Disease"},{"id":"T409","span":{"begin":363,"end":371},"obj":"Disease"},{"id":"T410","span":{"begin":878,"end":886},"obj":"Disease"},{"id":"T411","span":{"begin":889,"end":898},"obj":"Disease"},{"id":"T412","span":{"begin":1102,"end":1110},"obj":"Disease"},{"id":"T413","span":{"begin":1138,"end":1146},"obj":"Disease"},{"id":"T414","span":{"begin":1197,"end":1209},"obj":"Disease"},{"id":"T415","span":{"begin":1215,"end":1225},"obj":"Disease"},{"id":"T416","span":{"begin":1482,"end":1490},"obj":"Disease"},{"id":"T417","span":{"begin":1493,"end":1502},"obj":"Disease"},{"id":"T418","span":{"begin":1730,"end":1738},"obj":"Disease"},{"id":"T419","span":{"begin":1750,"end":1760},"obj":"Disease"},{"id":"T420","span":{"begin":1827,"end":1835},"obj":"Disease"}],"attributes":[{"id":"A406","pred":"mondo_id","subj":"T406","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A407","pred":"mondo_id","subj":"T407","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A408","pred":"mondo_id","subj":"T408","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A409","pred":"mondo_id","subj":"T409","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A410","pred":"mondo_id","subj":"T410","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A411","pred":"mondo_id","subj":"T411","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A412","pred":"mondo_id","subj":"T412","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A413","pred":"mondo_id","subj":"T413","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A414","pred":"mondo_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A415","pred":"mondo_id","subj":"T415","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A416","pred":"mondo_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A417","pred":"mondo_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A418","pred":"mondo_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A419","pred":"mondo_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A420","pred":"mondo_id","subj":"T420","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The emergence of the SARS-CoV-2 virus and the ensuing global pandemic has presented unprecedented healthcare and economic challenges. A key clinical feature of severe COVID-19 seems to be a highly prothrombotic state, which is linked to excess rates of arterial, venous and microvascular thrombosis, and adverse clinical outcomes. Emerging evidence suggests that SARS-CoV-2 can infect endothelial cells with the associated immune response and ensuing activation of inflammatory pathways resulting in dysregulation of the endothelium, leukocyte activation, NET generation, complement deposition, and platelet consumption. These pathways can conspire to unleash a prothrombotic state (immunothrombosis), which may result in significant thrombotic complications. Accordingly, there remains much interest, and an urgent clinical need, to precisely delineate the mechanisms by which SARS-CoV-2 infection causes thrombotic complications in the hope that new insights into this process will yield novel therapeutic approaches. This is especially pressing in the absence of an effective therapy or vaccine for SARS-CoV-2. Thus, in the context of COVID-19 the intersection of innate and adaptive immunity, inflammation, and thrombosis has been thrust into the global spotlight, and the challenge is now to urgently find therapeutic concepts to disrupt this unholy trinity in the face of a global pandemic. The growing awareness and understanding of thrombotic complications in patients with SARS-CoV-2 infection will contribute to a more rigorous diagnostic approach resulting in the earlier detection of thrombotic events. Importantly, the shift towards the early institution of antithrombotic therapy for the prevention and treatment of COVID-19-associated thrombosis will hopefully translate into improved outcomes for patients with COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T592","span":{"begin":32,"end":37},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T593","span":{"begin":70,"end":73},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T594","span":{"begin":134,"end":135},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T595","span":{"begin":188,"end":189},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T596","span":{"begin":253,"end":261},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T597","span":{"begin":253,"end":261},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"},{"id":"T598","span":{"begin":385,"end":402},"obj":"http://purl.obolibrary.org/obo/CL_0000115"},{"id":"T599","span":{"begin":451,"end":461},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T600","span":{"begin":521,"end":532},"obj":"http://purl.obolibrary.org/obo/UBERON_0001986"},{"id":"T601","span":{"begin":544,"end":554},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T602","span":{"begin":660,"end":661},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T603","span":{"begin":1226,"end":1229},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T604","span":{"begin":1370,"end":1374},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T605","span":{"begin":1378,"end":1379},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T606","span":{"begin":1522,"end":1523},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The emergence of the SARS-CoV-2 virus and the ensuing global pandemic has presented unprecedented healthcare and economic challenges. A key clinical feature of severe COVID-19 seems to be a highly prothrombotic state, which is linked to excess rates of arterial, venous and microvascular thrombosis, and adverse clinical outcomes. Emerging evidence suggests that SARS-CoV-2 can infect endothelial cells with the associated immune response and ensuing activation of inflammatory pathways resulting in dysregulation of the endothelium, leukocyte activation, NET generation, complement deposition, and platelet consumption. These pathways can conspire to unleash a prothrombotic state (immunothrombosis), which may result in significant thrombotic complications. Accordingly, there remains much interest, and an urgent clinical need, to precisely delineate the mechanisms by which SARS-CoV-2 infection causes thrombotic complications in the hope that new insights into this process will yield novel therapeutic approaches. This is especially pressing in the absence of an effective therapy or vaccine for SARS-CoV-2. Thus, in the context of COVID-19 the intersection of innate and adaptive immunity, inflammation, and thrombosis has been thrust into the global spotlight, and the challenge is now to urgently find therapeutic concepts to disrupt this unholy trinity in the face of a global pandemic. The growing awareness and understanding of thrombotic complications in patients with SARS-CoV-2 infection will contribute to a more rigorous diagnostic approach resulting in the earlier detection of thrombotic events. Importantly, the shift towards the early institution of antithrombotic therapy for the prevention and treatment of COVID-19-associated thrombosis will hopefully translate into improved outcomes for patients with COVID-19."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T169","span":{"begin":423,"end":438},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T170","span":{"begin":534,"end":554},"obj":"http://purl.obolibrary.org/obo/GO_0045321"},{"id":"T171","span":{"begin":1197,"end":1209},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"The emergence of the SARS-CoV-2 virus and the ensuing global pandemic has presented unprecedented healthcare and economic challenges. A key clinical feature of severe COVID-19 seems to be a highly prothrombotic state, which is linked to excess rates of arterial, venous and microvascular thrombosis, and adverse clinical outcomes. Emerging evidence suggests that SARS-CoV-2 can infect endothelial cells with the associated immune response and ensuing activation of inflammatory pathways resulting in dysregulation of the endothelium, leukocyte activation, NET generation, complement deposition, and platelet consumption. These pathways can conspire to unleash a prothrombotic state (immunothrombosis), which may result in significant thrombotic complications. Accordingly, there remains much interest, and an urgent clinical need, to precisely delineate the mechanisms by which SARS-CoV-2 infection causes thrombotic complications in the hope that new insights into this process will yield novel therapeutic approaches. This is especially pressing in the absence of an effective therapy or vaccine for SARS-CoV-2. Thus, in the context of COVID-19 the intersection of innate and adaptive immunity, inflammation, and thrombosis has been thrust into the global spotlight, and the challenge is now to urgently find therapeutic concepts to disrupt this unholy trinity in the face of a global pandemic. The growing awareness and understanding of thrombotic complications in patients with SARS-CoV-2 infection will contribute to a more rigorous diagnostic approach resulting in the earlier detection of thrombotic events. Importantly, the shift towards the early institution of antithrombotic therapy for the prevention and treatment of COVID-19-associated thrombosis will hopefully translate into improved outcomes for patients with COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T190","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"T191","span":{"begin":134,"end":330},"obj":"Sentence"},{"id":"T192","span":{"begin":331,"end":620},"obj":"Sentence"},{"id":"T193","span":{"begin":621,"end":759},"obj":"Sentence"},{"id":"T194","span":{"begin":760,"end":1019},"obj":"Sentence"},{"id":"T195","span":{"begin":1020,"end":1113},"obj":"Sentence"},{"id":"T196","span":{"begin":1114,"end":1396},"obj":"Sentence"},{"id":"T197","span":{"begin":1397,"end":1614},"obj":"Sentence"},{"id":"T198","span":{"begin":1615,"end":1836},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The emergence of the SARS-CoV-2 virus and the ensuing global pandemic has presented unprecedented healthcare and economic challenges. A key clinical feature of severe COVID-19 seems to be a highly prothrombotic state, which is linked to excess rates of arterial, venous and microvascular thrombosis, and adverse clinical outcomes. Emerging evidence suggests that SARS-CoV-2 can infect endothelial cells with the associated immune response and ensuing activation of inflammatory pathways resulting in dysregulation of the endothelium, leukocyte activation, NET generation, complement deposition, and platelet consumption. These pathways can conspire to unleash a prothrombotic state (immunothrombosis), which may result in significant thrombotic complications. Accordingly, there remains much interest, and an urgent clinical need, to precisely delineate the mechanisms by which SARS-CoV-2 infection causes thrombotic complications in the hope that new insights into this process will yield novel therapeutic approaches. This is especially pressing in the absence of an effective therapy or vaccine for SARS-CoV-2. Thus, in the context of COVID-19 the intersection of innate and adaptive immunity, inflammation, and thrombosis has been thrust into the global spotlight, and the challenge is now to urgently find therapeutic concepts to disrupt this unholy trinity in the face of a global pandemic. The growing awareness and understanding of thrombotic complications in patients with SARS-CoV-2 infection will contribute to a more rigorous diagnostic approach resulting in the earlier detection of thrombotic events. Importantly, the shift towards the early institution of antithrombotic therapy for the prevention and treatment of COVID-19-associated thrombosis will hopefully translate into improved outcomes for patients with COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1831","span":{"begin":556,"end":559},"obj":"Gene"},{"id":"1832","span":{"begin":21,"end":31},"obj":"Species"},{"id":"1833","span":{"begin":363,"end":373},"obj":"Species"},{"id":"1834","span":{"begin":1102,"end":1112},"obj":"Species"},{"id":"1835","span":{"begin":1468,"end":1476},"obj":"Species"},{"id":"1836","span":{"begin":1813,"end":1821},"obj":"Species"},{"id":"1837","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"1838","span":{"begin":288,"end":298},"obj":"Disease"},{"id":"1839","span":{"begin":683,"end":699},"obj":"Disease"},{"id":"1840","span":{"begin":734,"end":758},"obj":"Disease"},{"id":"1841","span":{"begin":883,"end":898},"obj":"Disease"},{"id":"1842","span":{"begin":906,"end":930},"obj":"Disease"},{"id":"1843","span":{"begin":1138,"end":1146},"obj":"Disease"},{"id":"1844","span":{"begin":1197,"end":1209},"obj":"Disease"},{"id":"1845","span":{"begin":1215,"end":1225},"obj":"Disease"},{"id":"1846","span":{"begin":1440,"end":1464},"obj":"Disease"},{"id":"1847","span":{"begin":1482,"end":1502},"obj":"Disease"},{"id":"1848","span":{"begin":1596,"end":1606},"obj":"Disease"},{"id":"1849","span":{"begin":1730,"end":1738},"obj":"Disease"},{"id":"1850","span":{"begin":1750,"end":1760},"obj":"Disease"},{"id":"1851","span":{"begin":1827,"end":1835},"obj":"Disease"}],"attributes":[{"id":"A1831","pred":"tao:has_database_id","subj":"1831","obj":"Gene:2004"},{"id":"A1832","pred":"tao:has_database_id","subj":"1832","obj":"Tax:2697049"},{"id":"A1833","pred":"tao:has_database_id","subj":"1833","obj":"Tax:2697049"},{"id":"A1834","pred":"tao:has_database_id","subj":"1834","obj":"Tax:2697049"},{"id":"A1835","pred":"tao:has_database_id","subj":"1835","obj":"Tax:9606"},{"id":"A1836","pred":"tao:has_database_id","subj":"1836","obj":"Tax:9606"},{"id":"A1837","pred":"tao:has_database_id","subj":"1837","obj":"MESH:C000657245"},{"id":"A1838","pred":"tao:has_database_id","subj":"1838","obj":"MESH:D013927"},{"id":"A1840","pred":"tao:has_database_id","subj":"1840","obj":"MESH:D013927"},{"id":"A1841","pred":"tao:has_database_id","subj":"1841","obj":"MESH:C000657245"},{"id":"A1842","pred":"tao:has_database_id","subj":"1842","obj":"MESH:D013927"},{"id":"A1843","pred":"tao:has_database_id","subj":"1843","obj":"MESH:C000657245"},{"id":"A1844","pred":"tao:has_database_id","subj":"1844","obj":"MESH:D007249"},{"id":"A1845","pred":"tao:has_database_id","subj":"1845","obj":"MESH:D013927"},{"id":"A1846","pred":"tao:has_database_id","subj":"1846","obj":"MESH:D013927"},{"id":"A1847","pred":"tao:has_database_id","subj":"1847","obj":"MESH:C000657245"},{"id":"A1848","pred":"tao:has_database_id","subj":"1848","obj":"MESH:D013927"},{"id":"A1849","pred":"tao:has_database_id","subj":"1849","obj":"MESH:C000657245"},{"id":"A1850","pred":"tao:has_database_id","subj":"1850","obj":"MESH:D013927"},{"id":"A1851","pred":"tao:has_database_id","subj":"1851","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The emergence of the SARS-CoV-2 virus and the ensuing global pandemic has presented unprecedented healthcare and economic challenges. A key clinical feature of severe COVID-19 seems to be a highly prothrombotic state, which is linked to excess rates of arterial, venous and microvascular thrombosis, and adverse clinical outcomes. Emerging evidence suggests that SARS-CoV-2 can infect endothelial cells with the associated immune response and ensuing activation of inflammatory pathways resulting in dysregulation of the endothelium, leukocyte activation, NET generation, complement deposition, and platelet consumption. These pathways can conspire to unleash a prothrombotic state (immunothrombosis), which may result in significant thrombotic complications. Accordingly, there remains much interest, and an urgent clinical need, to precisely delineate the mechanisms by which SARS-CoV-2 infection causes thrombotic complications in the hope that new insights into this process will yield novel therapeutic approaches. This is especially pressing in the absence of an effective therapy or vaccine for SARS-CoV-2. Thus, in the context of COVID-19 the intersection of innate and adaptive immunity, inflammation, and thrombosis has been thrust into the global spotlight, and the challenge is now to urgently find therapeutic concepts to disrupt this unholy trinity in the face of a global pandemic. The growing awareness and understanding of thrombotic complications in patients with SARS-CoV-2 infection will contribute to a more rigorous diagnostic approach resulting in the earlier detection of thrombotic events. Importantly, the shift towards the early institution of antithrombotic therapy for the prevention and treatment of COVID-19-associated thrombosis will hopefully translate into improved outcomes for patients with COVID-19."}